Empagliflozin 10 mg Tablets: Uses, Benefits & Complete Safety Guide
EMPATECH 10 contains Empagliflozin 10 mg and is marketed by Steris Healthcare. Empagliflozin is a prescription medicine belonging to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It is primarily used to improve blood-glucose control in adults with type 2 diabetes mellitus and may also have important cardiovascular and kidney-related benefits in appropriately selected patients.
What is Empagliflozin 10 mg Used For?
Empagliflozin 10 mg is used as part of a comprehensive treatment plan for adults with type 2 diabetes. It may be prescribed alone or together with other antidiabetic medicines, depending on individual treatment requirements.
Empagliflozin may also be prescribed for certain adults with heart failure or chronic kidney disease, including some patients who do not have diabetes, depending on the specific indication and clinical assessment.
The medicine is not intended to treat type 1 diabetes or diabetic ketoacidosis. A healthcare professional should determine whether EMPATECH 10 is appropriate based on the patient's diagnosis, kidney function, cardiovascular status and other medicines.
Why is Empagliflozin 10 mg Important?
Type 2 diabetes occurs when the body cannot use insulin effectively and/or does not produce enough insulin to maintain normal blood-glucose levels. Persistently elevated glucose can contribute to complications affecting the heart, kidneys, eyes, nerves and blood vessels.
Empagliflozin takes a different approach from many traditional glucose-lowering medicines. Instead of relying primarily on increased insulin production, it works through the kidneys to remove excess glucose from the body in urine.
This mechanism can lower blood glucose while also producing mild increases in urinary glucose and sodium excretion. Clinical use of SGLT2 inhibitors has also established important benefits for selected patients with cardiovascular and kidney disease.
Key Benefits
What are the Benefits?
When appropriately prescribed, Empagliflozin 10 mg may provide several therapeutic benefits:
Helps lower elevated blood glucose in adults with type 2 diabetes.
Supports improved glycemic control alongside diet and physical activity.
Promotes urinary excretion of excess glucose.
May help reduce the risk of hospitalization for heart failure in appropriate patients.
Provides kidney-protective benefits in selected patients with chronic kidney disease.
May contribute to modest weight reduction through urinary glucose loss.
Can be used with other diabetes medicines when additional glucose control is required.
The extent of benefit varies according to the individual's health, kidney function, existing treatment and clinical indication.
Side Effects
Like other medicines, EMPATECH 10 can cause side effects. Common or clinically relevant effects may include:
Increased urination
Increased thirst
Genital fungal infections
Urinary tract infections
Mild dehydration
Dizziness, particularly when blood pressure falls
Increased urination at night
Changes in blood lipid levels
The risk of low blood glucose is generally lower when empagliflozin is used alone, but hypoglycemia can become more likely when it is combined with insulin or sulfonylureas.
Serious Side Effects
Seek immediate medical attention if symptoms suggest a serious reaction, including:
Nausea, vomiting, abdominal pain or unusual tiredness with difficulty breathing, which may indicate diabetic ketoacidosis
Severe dehydration or fainting
Serious urinary or genital infection
Severe allergic reaction
Swelling of the face, lips, tongue or throat
Severe pain, redness or swelling around the genital or perineal region accompanied by fever or feeling unwell
Empagliflozin-associated ketoacidosis can occasionally occur even when blood glucose is not extremely high, so characteristic symptoms should not be ignored.
Available Substitute
The most appropriate substitute depends on the reason for treatment.
Depending on the clinical situation, a healthcare professional may consider another SGLT2 inhibitor, such as dapagliflozin, or a different class of medicine such as metformin, a GLP-1 receptor agonist, DPP-4 inhibitor, sulfonylurea or insulin.
For heart failure or chronic kidney disease, the choice of treatment depends on the specific diagnosis and current guideline-based therapy.
Substitution should not be based only on the strength printed on the package because different medicines have different indications, dosing schedules and safety considerations.
Dosage Guidelines
The usual starting dose of empagliflozin for many adult indications is 10 mg once daily, but the appropriate regimen depends on the condition being treated and the patient's kidney function.
Take EMPATECH 10 exactly as prescribed.
Important considerations include:
Take the medicine at approximately the same time each day.
It can generally be taken with or without food.
Maintain adequate hydration unless your healthcare professional has instructed you to restrict fluids.
Do not double the dose after a missed dose.
Continue prescribed dietary and physical-activity measures.
Regular monitoring may be required depending on the indication.
Kidney function should be assessed before and during treatment when clinically appropriate because renal function affects the suitability and effectiveness of empagliflozin.
Precautions & Warnings
Before taking Empagliflozin 10 mg, inform your healthcare professional if you have:
Kidney disease
Low blood pressure
Recurrent urinary tract infections
Recurrent genital infections
A history of diabetic ketoacidosis
Dehydration
Heart disease or heart failure
A planned surgical procedure
A prolonged period of fasting or significantly reduced food intake
A history of pancreatitis or other significant medical conditions
Empagliflozin can increase urine production and fluid loss. Patients taking diuretics or those who are prone to dehydration may require closer monitoring.
Mechanism of Action
Empagliflozin selectively inhibits sodium-glucose cotransporter-2 (SGLT2), a protein located primarily in the proximal tubules of the kidneys.
Normally, SGLT2 reabsorbs a substantial proportion of filtered glucose back into the bloodstream. By blocking SGLT2, empagliflozin reduces glucose reabsorption and increases the amount of glucose eliminated through urine.
This produces several effects:
Reduced blood-glucose levels
Increased urinary glucose excretion
Mild osmotic diuresis
Increased sodium excretion
Reduced intraglomerular pressure in appropriate patients
These mechanisms help explain why empagliflozin can have effects extending beyond glucose control, including benefits for certain patients with heart failure and chronic kidney disease.
Conclusion
EMPATECH 10, containing Empagliflozin 10 mg and marketed by Steris Healthcare, is an SGLT2 inhibitor used primarily for type 2 diabetes and, in appropriate patients, for selected cardiovascular and kidney-related conditions.
Its distinctive mechanism works through the kidneys by reducing glucose reabsorption and increasing urinary glucose excretion. This can improve blood-glucose control and may provide additional heart and kidney benefits in appropriately selected patients.
Patients should take EMPATECH 10 according to professional medical advice and maintain appropriate hydration and lifestyle measures. Particular attention should be given to symptoms of dehydration, genital or urinary infections and diabetic ketoacidosis. Kidney function and the patient's overall medical condition should be considered when initiating or continuing treatment.
EMPATECH 10 should be used under qualified medical supervision and should not be started, stopped or substituted without appropriate medical advice.
Comments
Post a Comment